Helius Medical Technologies, Inc. (Nasdaq: HSDT) has announced that CignaHealth has authorized claims for payment of the ...

CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of ...

Helius Medical Technologies (NASDAQ:HSDT) on Wednesday has priced its public offering, that includes 2,768,600 Class A common ...

Helius Medical Technologies Inc. has initiated a process to explore a range of "strategic alternatives" — everything from a reverse merger to a licensing deal — to boost stockholder value.

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Helius Medical Technologies, Inc. announced agreements with warrant holders to exercise nearly 4.97 million shares of common stock at a reduced price of $0.751 per share, generating approximately ...

ByInvesting.com • May 02, 2025 HSDT stock touches 52-week low at $0.26 amid sharp annual decline Helius Medical Technologies Inc. (NASDAQ:HSDT) stock has reached a new 52-week low, trading at $0.26.

NEWTOWN, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on ...

June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem ...